{"id":"NCT02396212","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA","officialTitle":"An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-07","primaryCompletion":"2017-03-07","completion":"2018-08-01","firstPosted":"2015-03-24","resultsPosted":"2019-09-13","lastUpdate":"2019-09-13"},"enrollment":19,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Juvenile Idiopathic Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Canakinumab","otherNames":["ACZ885"]}],"arms":[{"label":"Canakinumab","type":"EXPERIMENTAL"}],"summary":"This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile Idiopathic Arthritis (SJIA). Interim analysis (IA) data at Week 28 and 48 from this study supported a registration submission of canakinumab in the indication of SJIA in Japan.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved a Minimum Adapted American College of Rheumatology (ACR) Pediatric 30 Criteria","timeFrame":"Week 8","effectByArm":[{"arm":"Canakinumab 4 mg/kg Every 4 Weeks","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["32552266"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":19},"commonTop":["Nasopharyngitis","Constipation","Gastroenteritis","Headache","Injection site reaction"]}}